DIOGENX
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The company, which also has research labs in Nice, France, aims to discover and develop a candidate molecule that regenerates pancreatic insulin-producing cells in patients with diabetes, offering benefits in terms of quality of life and survival. It was discovered in the laboratory of Dr. Patrick Collombat (Inserm, CNRS, Nice University) in France, DiogenX is developing an innovative therapy with the potential to be the first beta-cell regeneration drug for diabetes.
DIOGENX
Industry:
Biotechnology Life Science
Founded:
2019-01-01
Address:
Marseille, Provence-Alpes-Cote D'Azur, France
Country:
France
Website Url:
http://www.diogenx.com
Total Employee:
1+
Status:
Active
Total Funding:
4.5 M EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics WordPress Google Universal Analytics Font Awesome Apache
Similar Organizations
Axcella
Axcella is a biotechnology company that treats diseases using endogenous metabolic modulators.
Novellus
Novellus is a biotechnology company working to develop engineered cellular medicines.
RNAimmune
RNAimmune is a biopharmaceutical company specializing in the discovery and development of mRNA-based therapeutics and vaccines.
Current Advisors List
Current Employees Featured
Founder
Investors List
JDRF T1D Fund
JDRF T1D Fund investment in Seed Round - DiogenX
AdBio partners
AdBio partners investment in Seed Round - DiogenX
Boehringer Ingelheim Venture Fund
Boehringer Ingelheim Venture Fund investment in Seed Round - DiogenX
Official Site Inspections
http://www.diogenx.com
- Host name: cluster029.hosting.ovh.net
- IP address: 51.91.236.255
- Location: France
- Latitude: 48.8582
- Longitude: 2.3387
- Timezone: Europe/Paris
More informations about "DiogenX"
Home - DioGenX
Nov 12, 2024 DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new …See details»
DiogenX - Crunchbase Company Profile & Funding
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type …See details»
About us - DioGenX
The company is developing first-in-class recombinant proteins designed for the treatment of T1D. DiogenX’s lead program DGX-01 modulates the Wnt/β-catenin signalling pathway to …See details»
DiogenX Company Profile | Management and Employees List
DiogenX Profile and History. DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for …See details»
DiogenX raises €27.5M Series A financing to advance its first-in …
DiogenX previously raised €4.5M ($4.8M) in June 2020. DiogenX’s lead program aims to regenerate pancreatic insulin-producing beta cells using ... the leading global organization …See details»
DiogenX - Funding, Financials, Valuation & Investors - Crunchbase
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators. New. Resources. Advanced Search. ... How much funding has this …See details»
DiogenX - VentureRadar
" DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients …See details»
DiogenX Company Profile - Office Locations, Competitors ... - Craft
DiogenX is a company that develops therapeutic solutions intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of type 1 and type 2 …See details»
DiogenX - EU-Startups
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). Its aim is …See details»
DiogenX - Org Chart, Teams, Culture & Jobs - The Org
DiogenX is a preclinical stage biotech company, specializing in the development of pancreatic beta-cell modulators for the treatment of Type 1 (T1D) and Type 2 Diabetes (T2D). The …See details»
Diogenx 2025 Company Profile: Valuation, Funding & Investors
Diogenx General Information Description. Developer of therapeutic services intended to serve diabetic patients. The company provides pancreatic beta-cell modulators for the treatment of …See details»
DiogenX - Contacts, Employees, Board Members, Advisors & Alumni
DiogenX is a preclinical stage biotech company specializing in the development of pancreatic beta-cell modulators. New. ... Pricing. Log In. Log In. Experience the new Crunchbase, …See details»
DiogenX - Sunstone
DiogenX is developing a first-in-class recombinant protein that aims to replicate insulin-producing beta cells in the pancreas of type 1 diabetes patients. This novel approach has the potential to …See details»
DiogenX - Overview, News & Similar companies | ZoomInfo.com
Who is DiogenX. DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics opti ons for millions of …See details»
Our approach - DioGenX
In this context, DiogenX’s approach has a unique off-the shelf profile for symptomatic T1D patients. With the potential to regenerate the patient’s own beta cell and restore its own …See details»
DiogenX Company Information - Funding, Investors, and More
DiogenX is a regenerative diabetes treatment founded in 2019 by Jean-Pascal Tranié, Benjamin Charles and Patrick Collombat. Seedtable Score 76 Startups. 2. Funding Rounds. $35.1m. …See details»
DiogenX | The Pharmaletter
Jul 25, 2024 The company is developing first-in-class recombinant proteins designed for the treatment of T1D. DiogenX’s lead program DGX-01 modulates the Wnt/β-catenin signalling …See details»
Beta-cell recovery to counter diabetes | DiogenX - CORDIS
Dec 8, 2023 DiogenX aims to withdraw insulin dependency and cure T1D by regenerating pancreatic beta-cell to allow autonomous insulin release in response to blood glucose levels …See details»
DiogenX raises €27.5M Series A financing to advance its first-in …
Marseille, France, May 10, 2023 – DiogenX, a regenerative medicine biotech company focused on regenerating insulin-producing beta cells for the treatment of diabetes, today announced …See details»
DiogenX raises $30M for regenerative diabetes treatment
May 12, 2023 DiogenX announced that it completed a $30 million Series A financing round to support its regenerating insulin-producing beta cells. Marseille, France-based DiogenX aims to …See details»